Navigation Links
PRA SPEAKING EVENT: Phase I Studies with Hepatitis C Compounds in Healthy Volunteers and Patients: Views from Inside
Date:4/8/2009

RALEIGH, N.C., April 8 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces Dr. Andre van Vliet, Vice President of Medical Affairs - Early Development Services (EDS), will host an audio conference on the development of New Chemical Entities (NCEs) in the treatment of hepatitis C. This interactive session will take place on April 14, 2009 at 11:30 am (ET). Drawing on his 19 years of experience in this field, Dr. van Vliet will provide an inside look at opportunities and obstacles when developing a hepatitis C compound including critical steps to optimize the success potential of an NCE as well as pitfalls and obstacles.

Dr. Andre van Vliet is a Board Certified internist, with expertise and training in oncology and clinical Pharmacology. His published materials include a recent article for the American Gastroenterological Association Institute on hepatitis C. Since 1995, he has supervised all aspects of Phase I and IIa drug research for PRA's EDS group.

With 228 beds in Europe and the U.S., and an innovative Phase I model that brings the center to the patients in Central/Eastern Europe, PRA's EDS group provides comprehensive services for Phase I and Phase IIa studies. In the Netherlands, PRA EDS initiated the "Dutch Hepatitis Research Initiative." In this unique research collaboration, PRA EDS collaborates with the Amsterdam Medical Centre and the Rotterdam Erasmus Medical Centre. In PRA's Product Registration group (Phase II and III), over a third of its project management and clinical operations employees are experienced in infectious diseases clinical research.

The deadline for registration is Monday, April 13, 2009. To learn more about the audio conference, click http://www.prainternational.com/portal/page/portal/PRAINTL/News%20%20Events/Events/Popup. To register, clickhttp://www.fxconferences.com/Phase-I-Studies-with-Hepatitis-C-Compounds-in-Healthy-Volunteers-and-Patients-Views-from-Inside-P317.aspx

About PRA International

PRA International is a global Clinical Research Organization providing services through all phases of clinical development. Although we specialize in Infectious Diseases, Oncology, CNS, Respiratory/Allergy and Cardiovascular, we perform studies in all therapeutic areas. PRA has supported over 2,100 clinical trials through its 35 global offices. PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge, enable our project teams to deliver consistent and on time performance for our clients.

To learn more about PRA International, please visit http://www.prainternational.com, email endpoints@praintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PRA International Speaking Event: Beyond Global Feasibility
2. PRA International Speaking Event: Rational Drug Design and Development in Infectious Diseases
3. Folic acid survey of Spanish-speaking women finds most are missing benefits, March of Dimes says
4. First Nationwide Folic Acid Survey of Spanish-Speaking Women Finds Most Are Missing Benefits, March of Dimes Says
5. Newport Introduces More Resources for Spanish Speaking Plan Participants
6. Response rates to antidepressants differ among English- and Spanish-speaking Hispanics
7. When it comes to abstinence teens, adults arent speaking the same language
8. Children in non-English-speaking households face many health disparities, researcher concludes
9. Medpace Director of Clinical Pharmacology, Jim Wei, MD, PhD, Embarks on a Regulatory Policy Speaking Tour in China in May
10. Speaking of Womens Health Gives the Gift of Knowledge and Good Health This Mothers Day
11. Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Harrisburg, PA (PRWEB) , ... December 09, 2016 ... ... concussion education program through the Pennsylvania Cable Network (PCN) during the summer of ... Brain Injury Implementation Grant provided by the United States Department of Health and ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016 Research and Markets has announced ... report to their offering. ... The report forecasts the global optical transceiver market to ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
(Date:12/9/2016)... Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged ... rare diseases, today announced that senior management will participate in a ... at the InterContinental Barclay Hotel in New York City ... About aTyr Pharma ... aTyr Pharma is engaged in the discovery ...
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
Breaking Medicine Technology: